Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Markwin Velders brings over 18 years of management experience in biotechnology companies. He obtained his PhD from Leiden University in 1996. After a post-doc and associate professorship at Loyola University in Chicago, he became Chief Scientific Officer at AM-Pharma in 2004. After bringing two compounds from bench to bed at AM-Pharma, Markwin moved to TNO Biosciences as a Business Unit Manager, managing a group of 150 professionals. Since 2011 he has been independently active as Prime Life Science, assisting various start-up and early life science companies with their strategy, financing, business development and interim management. He has been involved in the start-up of several new ventures, and secured funding for 4 Life Science start-ups.
End of 2013 Markwin became involved with a potential start up from the Netherland’s Cancer Institute (NKI) that was incorporated in 2014 and called T-cell Factory (TCF). Subsequently, he was instrumental in the M&A deal where Kite Pharma Inc. acquired TCF to form Kite Pharma EU B.V. Since March 2015 he is Vice President Operations and Managing Director of Kite Pharma EU B.V. in Amsterdam.
As of June 2017 Markwin is chairman of the board of HollandBio, the branch association for Biotech in the Netherlands.